{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:57:25Z","timestamp":1787169445822,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors have significantly advanced research in oncology and are used to successfully treat patients with bladder cancer (BC). However, as the benefits of programmed death-1\/ programmed death-ligand-1 blockade immunotherapy do not extend to all patients with BC, biomarkers are required to improve prognostic stratification. This study aims to identify reliable biomarkers to enhance the prediction of treatment outcomes. Bulk RNA expression data from a BC cohort (GSE176307) receiving ICI and single-cell sequencing data from patients with BC (GSE135337) were collected. We identified differentially expressed genes (DEGs) within cells that were associated with favorable survival outcomes and developed a predictive bladder cancer gene signature (BC-GS). Subsequently, we performed pathway enrichment analysis using the Reactome database. We used two independent datasets to validate the BC-GS. Patients with low BC-GS had a significantly shorter overall survival (OS) than those with high BC-GS (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001, respectively). Additionally, patients with a concurrently low BC-GS score and low tumor mutation burden (TMB) in GSE176307 and the two validation datasets exhibited an increased risk of death. Genes in the BC-GS were predominantly involved in CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell activation, antigen presentation, and immune checkpoint pathways. CIBERSORT analysis revealed differences in CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells and macrophages between the high and low BC-GS groups. This study demonstrated the prognostic significance of the BC-GS in patients with BC treated with ICI. The combined assessment of the BC-GS and TMB may provide a sophisticated prognostic approach to enhance patient stratification for ICI treatment in BC.\n                  <\/jats:p>","DOI":"10.1007\/s00262-024-03839-7","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T07:58:43Z","timestamp":1734767923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Integration of bulk and single-cell RNA-seq reveals prognostic gene signatures in patients with bladder cancer treated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"74","author":[{"given":"Mina","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"1","key":"3839_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3839_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4111\/icu.20220031","volume":"64","author":"S Lim","year":"2023","unstructured":"Lim S, Park JH, Chang H (2023) Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model. Investig Clin Urol 64(1):74\u201381","journal-title":"Investig Clin Urol"},{"issue":"19","key":"3839_CR3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M et al (2023) Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 389(19):1778\u20131789","journal-title":"N Engl J Med"},{"issue":"3","key":"3839_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","volume":"34","author":"AV Balar","year":"2023","unstructured":"Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J et al (2023) Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol 34(3):289\u2013299","journal-title":"Ann Oncol"},{"issue":"13","key":"3839_CR5","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383(13):1218\u20131230","journal-title":"N Engl J Med"},{"issue":"11","key":"3839_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026","journal-title":"N Engl J Med"},{"issue":"10","key":"3839_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"issue":"4","key":"3839_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41587-021-01091-3","volume":"40","author":"D Sun","year":"2022","unstructured":"Sun D, Guan X, Moran AE, Wu LY, Qian DZ, Schedin P et al (2022) Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat Biotechnol 40(4):527\u2013538","journal-title":"Nat Biotechnol"},{"key":"3839_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00439-024-02663-4","volume":"143","author":"W Wang","year":"2024","unstructured":"Wang W, Chen G, Zhang W, Zhang X, Huang M, Li C et al (2024) The crucial prognostic signaling pathways of pancreatic ductal adenocarcinoma were identified by single-cell and bulk RNA sequencing data. Hum Genet 143:1109","journal-title":"Hum Genet"},{"issue":"7693","key":"3839_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548","journal-title":"Nature"},{"key":"3839_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33980-9","author":"JS Damrauer","year":"2022","unstructured":"Damrauer JS, Beckabir W, Klomp J, Zhou M, Plimack ER, Galsky MD et al (2022) Collaborative study from the bladder cancer advocacy network for the genomic analysis of metastatic urothelial cancer. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-022-33980-9","journal-title":"Nat Commun"},{"issue":"9","key":"3839_CR12","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","volume":"125","author":"TL Rose","year":"2021","unstructured":"Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM et al (2021) Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer 125(9):1251\u20131260","journal-title":"Br J Cancer"},{"issue":"12","key":"3839_CR13","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/ijc.33794","volume":"149","author":"H Lai","year":"2021","unstructured":"Lai H, Cheng X, Liu Q, Luo W, Liu M, Zhang M et al (2021) Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer. Int J Cancer 149(12):2099\u20132115","journal-title":"Int J Cancer"},{"key":"3839_CR14","doi-asserted-by":"crossref","unstructured":"Gao J, Arman Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. (2013) integrative analysis of complex cancer genomics and clinical Profiles Using the cBioPortal inTRODUcTiOn eQUiPMenT inSTRUcTiOnS Querying individual cancer Studies Viewing and interpreting the Results Performing cross-cancer Queries Viewing cancer Study Summary Data Viewing genomic alterations in a Single Tumor: Patient View Programmatic access nOTeS anD ReMaRKS complementary Data Sources and analysis Options Future Directions [Internet]. Vol. 6. 2013. Available from: http:\/\/www.adobe.com\/products\/illustrator.html","DOI":"10.1126\/scisignal.2004088"},{"key":"3839_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister C, Satija R (2019) Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. https:\/\/doi.org\/10.1186\/s13059-019-1874-1","journal-title":"Genome Biol"},{"key":"3839_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-021-03957-4","author":"RB Patterson-Cross","year":"2021","unstructured":"Patterson-Cross RB, Levine AJ, Menon V (2021) Selecting single cell clustering parameter values using subsampling-based robustness metrics. BMC Bioinform. https:\/\/doi.org\/10.1186\/s12859-021-03957-4","journal-title":"BMC Bioinform"},{"issue":"7","key":"3839_CR17","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM et al (2019) Comprehensive integration of single-cell data. Cell 177(7):1888-1902.e21","journal-title":"Cell"},{"issue":"13","key":"3839_CR18","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A et al (2021) Integrated analysis of multimodal single-cell data. Cell 184(13):3573-3587.e29","journal-title":"Cell"},{"key":"3839_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25960-2","author":"JW Squair","year":"2021","unstructured":"Squair JW, Gautier M, Kathe C, Anderson MA, James ND, Hutson TH et al (2021) Confronting false discoveries in single-cell differential expression. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-021-25960-2","journal-title":"Nat Commun"},{"key":"3839_CR20","unstructured":"Carlson M, Falcon S, Pages H, Li N. (2019) org. Hs. eg. db: Genome wide annotation for Human. R package version. 3(2):3"},{"issue":"2","key":"3839_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1039\/C5MB00663E","volume":"12","author":"G Yu","year":"2016","unstructured":"Yu G, He QY (2016) ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst 12(2):477\u2013479","journal-title":"Mol Biosyst"},{"key":"3839_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq537","author":"D Warde-Farley","year":"2010","unstructured":"Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P et al (2010) The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkq537","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"3839_CR23","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W et al (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"3839_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453\u2013457","journal-title":"Nat Methods"},{"key":"3839_CR25","first-page":"12","volume":"2","author":"D Zeng","year":"2021","unstructured":"Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y et al (2021) IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol 2:12","journal-title":"Front Immunol"},{"key":"3839_CR26","unstructured":"Therneau TM. (2020) A Package for Survival Analysis in R [Internet]. Available from: https:\/\/CRAN.R-project.org\/package=survival"},{"key":"3839_CR27","unstructured":"Alboukadel Kassambara, Marcin Kosinski and Przemyslaw Biecek (2020). survminer: Drawing Survival Curves using \u201cggplot2\u201d. R package version0.4.8. https:\/\/CRAN.R-project.org\/package=survminer"},{"key":"3839_CR28","unstructured":"R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/"},{"key":"3839_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S et al (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14\u201320","journal-title":"Immunity"},{"key":"3839_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02035","author":"TS Kapellos","year":"2019","unstructured":"Kapellos TS, Bonaguro L, Gem\u00fcnd I, Reusch N, Saglam A, Hinkley ER et al (2019) Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02035","journal-title":"Front Immunol"},{"key":"3839_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87720-y","author":"H Takiguchi","year":"2021","unstructured":"Takiguchi H, Yang CX, Yang CWT, Sahin B, Whalen BA, Milne S et al (2021) Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-87720-y","journal-title":"Sci Rep"},{"key":"3839_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"RY Ma","year":"2022","unstructured":"Ma RY, Black A, Qian BZ (2022) Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol 43:546\u201363","journal-title":"Trends Immunol"},{"issue":"2","key":"3839_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O\u2019Brien SA et al (2020) Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181(2):442-459.e29","journal-title":"Cell"},{"issue":"11","key":"3839_CR34","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-19-3231","volume":"26","author":"A Sathe","year":"2020","unstructured":"Sathe A, Grimes SM, Lau BT, Chen J, Suarez C, Huang RJ et al (2020) Single-cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment. Clin Cancer Res 26(11):2640\u20132653","journal-title":"Clin Cancer Res"},{"issue":"18","key":"3839_CR35","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1158\/0008-5472.CAN-22-1427","volume":"82","author":"E Timperi","year":"2022","unstructured":"Timperi E, Gueguen P, Molgora M, Magagna I, Kieffer Y, Lopez-Lastra S et al (2022) Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer. Cancer Res 82(18):3291\u20133306","journal-title":"Cancer Res"},{"key":"3839_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo GD, Kurzrock R (2021) The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39:154\u201373","journal-title":"Cancer Cell"},{"issue":"10","key":"3839_CR37","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1007\/s10147-023-02386-y","volume":"28","author":"H Nishiyama","year":"2023","unstructured":"Nishiyama H, Tsuzuki T, Ohyama C, Matsuyama H, Shinozaki K, Hayashi Y et al (2023) Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study. Int J Clin Oncol 28(10):1398\u20131410","journal-title":"Int J Clin Oncol"},{"key":"3839_CR38","doi-asserted-by":"publisher","first-page":"000442","DOI":"10.1136\/esmoopen-2018-000442","volume":"4","author":"R B\u00fcttner","year":"2019","unstructured":"B\u00fcttner R, Longshore JW, L\u00f3pez-R\u00edos F, Merkelbach-Bruse S, Normanno N, Rouleau E et al (2019) Implementing TMB measurement in clinical practice: Considerations on assay requirements. ESMO Open 4:000442","journal-title":"ESMO Open"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03839-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03839-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03839-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T12:50:13Z","timestamp":1738241413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03839-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3839"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03839-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"20 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"28"}}